


# Selection and Evaluation of a Third Rapid HIV Assay as a Tie Breaker to Enhance Early HIV Diagnosis and Linkage to Care in the Kingdom of Swaziland



**Authors:** Rogers Kisame<sup>1</sup>, Sindisiwe Susan Dlamini<sup>2</sup>

**Affiliations:** University Research Co., LLC (URC)<sup>1</sup> ; MoH, Swaziland Health Laboratory Services (SHLS)<sup>2</sup>, Mbabane, Swaziland.

Dec 03, 2014



ASLM2014 CONFERENCE  
30 NOVEMBER – 4 DECEMBER 2014 INNOVATION AND INTEGRATION OF  
LABORATORY AND CLINICAL SYSTEMS”




# BACKGROUND



- Swaziland continues to have the highest overall HIV prevalence rate in the world (31% among adults). Prevalence is higher in women (38%) compared to men (23%).
- A successful public health response to HIV, not only requires robust HIV testing program, but also requires successful linkages to HIV care and treatment.
- Since 2006, a 2 rapid test HIV serial testing algorithm was adopted (Determine®HIV-1/2 and Uni-Gold™ HIV-1/2) and centralized ELISA, as a 3rd test offered at NRL.


Algorithm Programmatic barriers at laboratory and community level:





# 'Looking beyond the laboratory optimize early detection and linkage to care'

## HIV Testing strategy for Diagnosis in High Prevalence Settings



**Notes:**  
 \*Assay A1, A2, A3 represent three different assays (of any test format). \*Report\* = result may be reported.  
<sup>1</sup> For newly diagnosed individuals, a positive result should be confirmed on a second specimen to rule out laboratory error.  
<sup>2</sup> Re-testing should be performed on a second specimen taken after 14 days to rule out seroconversion.  
<sup>3</sup> If A1 is an antigen/antibody detection assay and A2 or A3 is an antibody-detection-only assay, re-testing should be performed with a second specimen taken after 14 days.

**A1:** Determine      **A2:** Unigold      **A3:** ELISA (NRL)

OPEN ACCESS Freely available online



### The Evaluation of a Rapid *In Situ* HIV Confirmation Test in a Programme with a High Failure Rate of the WHO HIV Two-Test Diagnostic Algorithm

Derryck B. Klarkowski\*, Joseph M. Wazome, Kamalini M. Lokuge, Leslie Shanks, Clair F. Mills, Daniel P. O'Brien

Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands

Journal List > PLoS One > v. 8(3); 2013 > PMC3603939



PLoS One. 2013; 8(3): e59906.  
 Published online Mar 20, 2013. doi: [10.1371/journal.pone.0059906](https://doi.org/10.1371/journal.pone.0059906)

PMCID: PMC3603939

#### False Positive HIV Diagnoses in Resource Limited Settings: Operational Lessons Learned for HIV Programmes

Leslie Shanks,<sup>1\*</sup> Derryck Klarkowski,<sup>1</sup> and Daniel P. O'Brien<sup>1,2</sup>

Michael Schindler, Editor

[Author information](#) [Article notes](#) [Copyright and License information](#)

PLOS



# Goal and objectives

- **Goal:**
  - Introduce a third rapid HIV test as a tie breaker to boost early diagnosis and linkage to care in the country.
- **Objectives:**
  - To select 4 HIV rapid test kits (Phase 1).
  - Evaluate the performance a selected rapid test kit against a gold standard (Phase 2).
  - Review and recommend a 3<sup>rd</sup> rapid HIV test tie breaker algorithm for Swaziland (Phase 2).



# Method

5 months

## Phase 1 (July to Aug 2014): Candidate kit identification

### Preliminary kits selection

- Cost per test ( $\leq 8$  US dollars per test)
- WHO pre-qualification and USAID approval
- ISO 13485 CERTIFICATION
- Ability to perform testing on serum, plasma, or whole blood (venous/capillary)
- Specificity ( $\geq 99.9$  i.e. the specificity of 2nd HIV rapid assay in the serial algorithm for Swaziland)

### Determine comparative advantage

- Evaluate selected WHO-prequalified and USAID approved test against a pre determined criteria/checklist

## Phase 2 (Oct to Dec 2014)

### Determine:

- Sensitivity
  - Specificity
  - PPV
  - NPV
- \*CLSI guidelines

### Review HIV algorithm



# Selection Criteria ‘Comparative advantage’

Criteria	Grading /Score
Ease of use	6 score =Satisfactory
Number of reagents needed [1 for only 1 reagent and 0 for more than 1]	
Storage conditions [1 for 8 to 30°C required and 0 for 2 to 8°C required]	
Total number of assay steps [1 for less than 4 steps and 0 for more than 4 steps]	
Total performance time [1 for 15 min and 0 for more than 15 min]	
Technical skill needed by operator [1 for no lab experience and 0 for Lab experience]. Note: Sample size =20	
Shelf life [2 for ≥ 18 months and 1 for < 12 months]	2 score =Satisfactory
Packaging; Supply chain-allow for easy distribution of single tests to several sites, considering that tie breaker demand may relatively be low	
Overall packaging [1 for < 25 test per manufacturer package and 0 for > 25 test per manufacturer package]	
1, for test with individual buffer incorporated per test, and 0, for buffer shared by multiple tests within package.	
Availability of approved distributor in the SADC region [1 for yes and 0, for no]	1 score =Satisfactory
Post marketing evaluation; 1 for Good reputation and 0 for poor reputation (based on published evidence)	1 score =Satisfactory
ISO certification. 1 For certifies manufactures and 0 for non-certified manufacturers	1 score =Satisfactory
<b>Overall Result</b>	
Key	11 score =satisfactory
	10 scores =Area of Concern
	<10 scores =unsatisfactory



# Results : phase 1 preliminary kit selection

## Candidate kit identification criteria

- Cost per test ( $\leq 8$  US dollars per test)
- WHO pre-qualification and USAID approval
- ISO 13485 CERTIFICATION
- Ability to perform testing on serum, plasma, or whole blood (venous/capillary)
- Specificity ( $\geq 99.9$  i.e. the specificity of 2nd HIV rapid assay in the serial algorithm for Swaziland)

Identified kits included:

## 4 WHO-prequalified and USAID approved kits:

- DPP® HIV 1 / 2 (Chembio Diagnostic Systems, Inc);
- HIV 1/ 2 STAT-PAK® Assay (Chembio Diagnostic Systems, Inc)
- Clearview® COMPLETE HIV1/2 (Allele)
- SD Bioline HIV 1/2 3.0 (Standard Diagnostics)



# Results : 'Comparative advantage'

Criteria	Scores/ Results			
	DPP® HIV 1 / 2	HIV 1/ 2 STAT-PAK®	Clearview® COMPLETE HIV1/2	SD Bioline HIV 1/2 3.0
Ease of use	4=Unsatisfactory * Number of reagents needed	6=Satisfactory	6=Satisfactory	6=Satisfactory
Packaging	1=Unsatisfactory * buffer shared by multiple tests within package	1=Unsatisfactory * buffer shared by multiple tests within package	2=Satisfactory	1=Unsatisfactory * buffer shared by multiple tests within package
Availability in the region;	1=Satisfactory	1=Satisfactory	1=Satisfactory	
Post marketing evaluation;	1=Satisfactory	1=Satisfactory	1=Satisfactory	0=Unsatisfactory * product recall in 2012 (WHO, 2012)
ISO certification.	1=Satisfactory	1=Satisfactory	1=Satisfactory	1=Satisfactory
Overall Result	8=Unsatisfactory	10=Unsatisfactory	11=Satisfactory	8=Unsatisfactory



# Discussion and conclusion

- For Swaziland, results indicated comparative and excellent operational results for Clearview® COMPLETE HIV1/2 assay.
- These findings provide a basis for harmonizing national HIV rapid testing strategies and have future implication on maximizing HTC uptake and patient linkage to care and treatment.



# Way forward

- Conduct a broader laboratory based performance evaluation of selected assay against a gold standard test (ELISA).
  - Sensitivity, Specificity, positive predictive value, Negative Predictive Value
- Review and recommend an 3<sup>rd</sup> tie breaker HIV testing algorithm (serial).



# Acknowledgment

- MoH
- Management -Swaziland Health Laboratory Services
- SNAP

The work is made possible with the technical and financial support of the CDC/URC HIV/AIDS and TB related Laboratory support and Technical assistance project.

